{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:01:01Z","timestamp":1787014861783,"version":"build-2736575974"},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":3588,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Surgery"],"published-print":{"date-parts":[[1998,9]]},"abstract":"<jats:p>Objective\u2014To determine the antinociceptive effects of oxymorphone, butorphanol, and acepromazine individually and in combination to a noxious visceral stimulus in cats.<\/jats:p>\n                  <jats:p>Study Design\u2014Randomized, blinded controlled study.<\/jats:p>\n                  <jats:p>Animals\u2014Eight healthy mixed\u2010breed cats (four male, four female) weighing 4.4 \u00b1 1.2 kg and aged 1 to 2 years old.<\/jats:p>\n                  <jats:p>Methods\u2014A silastic balloon catheter was inserted per rectum and inflated at various pressures. Physiological parameters (respiratory rate, pulse rate, and blood pressure) were also recorded. Subjects were administered individual and combined intravenous (IV) doses of 0.025, 0.05, 0.10, and 0.20 mg\/kg oxymorphone and 0.025, 0.05, 0.10, and 0.20 mg\/kg butorphanol. A further study of various ratios of butorphanol and oxymorphone (3:1, 2:1, 1:1, 1:2, and 1:3), at a combined equivalent dose of 0.1 mg\/kg, was performed in four cats per dose combination. In a separate study, four cats were administered combined IV doses of 0.05 mg\/kg each of oxymorphone and butorphanol or 0.05 mg\/kg each of oxymorphone, butorphanol, and acepromazine.<\/jats:p>\n                  <jats:p>\n                    Results\u2014Combined doses of 0.05 and 0.10 mg\/kg of oxymorphone and butorphanol showed mainly additive with some synergistic antinociceptive interactions and the combined dose of 0.2 mg\/kg of each agent demonstrated additional antinociceptive effects,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .05. Additional studies showed that various ratios of the two agents at a total combined dose of 0.10 mg\/kg IV did not produce levels of antinociception that were significantly different from each other,\n                    <jats:italic>P<\/jats:italic>\n                    &gt; .05. Acepromazine (ACE) significantly increased the magnitude of antinociception at 15 minutes when administered in combination with oxymorphone and butorphanol,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .05. Also, physiological variables were unaffected by these drug combinations.\n                  <\/jats:p>\n                  <jats:p>Conclusions\u2014Low doses of oxymorphone and butorphanol in combination can produce greater levels of antinociception than when used individually. ACE, in conjunction with oxymorphone and butorphanol, produced even greater levels of antinociception than the two\u2010opioid drug combination.<\/jats:p>\n                  <jats:p>Clinical Relevance\u2014Oxymorphone, butorphanol, and ACE can be used in combination to produce additive or synergistic effects without adverse effects in cats. These data suggest that ACE and butorphanol at low doses given as preanesthetic medication followed by a mu opioid (eg, oxymorphone) after surgery at low doses may provide an effective method of pain management in the cat.<\/jats:p>","DOI":"10.1111\/j.1532-950x.1998.tb00158.x","type":"journal-article","created":{"date-parts":[[2008,2,29]],"date-time":"2008-02-29T04:23:52Z","timestamp":1204259032000},"page":"466-472","source":"Crossref","is-referenced-by-count":39,"title":["Antinociceptive Effects of Oxymorphone\u2010Butorphanol\u2010Acepromazine Combination in Cats"],"prefix":"10.1111","volume":"27","author":[{"given":"SHANNON L.","family":"BRIGGS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KRISTI","family":"SNEED","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DONALD C.","family":"SAWYER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"28","volume-title":"Principles and Practice of Veterinary Anesthesia","author":"Short CE","year":"1987"},{"key":"e_1_2_1_3_2","volume-title":"The complete handbook of approved new animal drug applications in the United States","author":"Shepard Carr","year":"1996"},{"key":"e_1_2_1_4_2","first-page":"160","article-title":"Oxymorphone, an effective analgesic in dogs and cats","volume":"143","author":"Palminteri A.","year":"1963","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_1_5_2","first-page":"257","article-title":"Does ketamine provide adequate visceral analgesia when used alone or in combination with acepromazine, diazepam, or butorphanol in cats?","volume":"29","author":"Sawyer DC","year":"1993","journal-title":"J Am Anim Hosp Assoc"},{"key":"e_1_2_1_6_2","first-page":"485","volume-title":"The Pharmacological Basis of Therapeutics (ed 8)","author":"Jaffe JH","year":"1990"},{"key":"e_1_2_1_7_2","first-page":"231","article-title":"The pharmacology of butorphanol, a 3,14 dihydroxymorphinan narcotic antagonist analgesic","volume":"220","author":"Pircio AW","year":"1976","journal-title":"Arch Intern Pharmacodyn"},{"key":"e_1_2_1_8_2","first-page":"283","article-title":"Pharmacology of Opioids","volume":"35","author":"Martin WR","year":"1984","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_9_2","first-page":"55","article-title":"Further evaluation of the discriminative effects of morphine in the rat","volume":"201","author":"Shannon HE","year":"1977","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_10_2","first-page":"374","article-title":"Use of beta\u2010funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands","volume":"241","author":"Zimmerman DM","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(81)90250-1"},{"key":"e_1_2_1_12_2","first-page":"95","article-title":"Further characterization of the three\u2010choice morphine, cyclazocine and saline discrimination paradigm: Opioids with agonist and antagonist properties","volume":"224","author":"White JM","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_13_2","first-page":"557","article-title":"Discriminative stimulus effects of mu and kappa opioids in the pigeon: Analysis of the effects of full and partial mu and kappa agonists","volume":"249","author":"Picker MJ","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_14_2","first-page":"89","article-title":"A kappa opioid effect: Increased urination in the rat","volume":"224","author":"Leander JD","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(83)90198-X"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(85)90059-6"},{"key":"e_1_2_1_17_2","first-page":"33","article-title":"Kappa agonist\u2010induced diuresis: Evidence for stereoselectivity, strain differences, independence of hydration variables and a result of decreased plasma vasopressin levels","volume":"242","author":"Leander JD","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(90)90256-H"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04700.x"},{"key":"e_1_2_1_20_2","first-page":"2333","article-title":"Limitations on the antagonist actions of opioid antagonists","volume":"41","author":"Young AM","year":"1982","journal-title":"Fed Proc"},{"key":"e_1_2_1_21_2","first-page":"442","article-title":"Antagonist and rate\u2010suppressing effects of opioid antagonists in the pigeon","volume":"235","author":"France CP","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442021"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.2460\/ajvr.1991.52.11.1826","article-title":"Dose response to butorphanol administered subcutaneously to increase visceral nociceptive threshold in dogs","volume":"52","author":"Sawyer DC","year":"1991","journal-title":"Am J Vet Res"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-950X.1994.tb00447.x"},{"key":"e_1_2_1_25_2","first-page":"247","volume-title":"Status of Ketamine Anesthesiology","author":"Sawyer DC","year":"1990"},{"key":"e_1_2_1_26_2","first-page":"267","volume-title":"Veterinary pharmacology and therapeutics (ed 5)","author":"Booth NH","year":"1987"},{"key":"e_1_2_1_27_2","volume-title":"Receptors in pharmacology","author":"Simon EJ","year":"1977"},{"key":"e_1_2_1_28_2","first-page":"413","article-title":"Kappa opioids in rhesus monkeys. Diuresis, sedation, analgesia and discriminative stimulus effects","volume":"242","author":"Dykstra LA","year":"1987","journal-title":"J Pharmacol Ther Exp"},{"key":"e_1_2_1_29_2","first-page":"425","article-title":"In vivo binding of benzomorphan to mu, delta, and kappa opioid receptors: Comparison with urine output in the rat","volume":"233","author":"Richards ML","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)91007-5"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(95)00140-R"},{"key":"e_1_2_1_32_2","unstructured":"SawyerDC StrilerEL BohartG.:Indirect blood pressure measurements in dogs cats and horses: Correlation with direct arterial pressures and site of measurement. Fifth International Congress of Veterinary Anesthesia Guelph Ontario August 22\u201325 1994."},{"key":"e_1_2_1_33_2","volume-title":"Principles and procedures of statistics, a biometrical approach","author":"Steel RGD","year":"1984"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7384811"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(81)90034-8"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1986.sp016184"},{"key":"e_1_2_1_37_2","first-page":"258","article-title":"Actions of mu, delta, and kappa opioid agonists and antagonists on mouse primary afferent neurons in culture","volume":"243","author":"Werz MA","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(92)90319-W"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)01333-D"},{"key":"e_1_2_1_40_2","first-page":"283","article-title":"C\u2010primary afferent fibre mediated inhibitions in the dorsal horn of the decerebrate\u2010spinal rat","volume":"51","author":"Woolfe CJ","year":"1983","journal-title":"Exp Brain Res"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-5616(92)50633-7"},{"key":"e_1_2_1_42_2","first-page":"800","article-title":"Properties of [3H] haloperidol and [3H] dopamine binding associated with dopamine receptors in calf brain membranes","volume":"12","author":"Burt DR","year":"1976","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_43_2","first-page":"141","article-title":"Rat striatal methionine\u2010enkephalin content after chronic treatment with cataleptogenic and noncataleptogenic antischizophrenic drugs","volume":"205","author":"Hong JS","year":"1978","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Veterinary Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1532-950X.1998.tb00158.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1532-950X.1998.tb00158.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1532-950X.1998.tb00158.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T18:01:10Z","timestamp":1708624870000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1532-950X.1998.tb00158.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1998,9]]}},"alternative-id":["10.1111\/j.1532-950X.1998.tb00158.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1532-950x.1998.tb00158.x","archive":["Portico"],"relation":{},"ISSN":["0161-3499","1532-950X"],"issn-type":[{"value":"0161-3499","type":"print"},{"value":"1532-950X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,9]]}}}